SL-801 not checked

Stemline Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).”In the company’s words, NCT02667873 on ClinicalTrials.gov
Tested for
Solid Tumors
Main trialPhase 1
“Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.”In the company’s words, NCT02667873 on ClinicalTrials.gov
Other names
Felezonexor

Other drugs for Solid Tumors

All 2440 drugs for Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 6 Oct 2021 A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SL-801

Following is part of Solo: you see every change to SL-801 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in